Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 260Lymphoma, Non-Hodgkin 205Leukemia, Lymphocytic, Chronic, B-Cell 193Lymphoma, Large B-Cell, Diffuse 187Lymphoma, Follicular 168Lymphoma, Mantle-Cell 134Leukemia 81Lymphoma, B-Cell, Marginal Zone 80Burkitt Lymphoma 54Waldenstrom Macroglobulinemia 52Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Lymphoma, B-Cell 47Lymphoma, Large-Cell, Immunoblastic 42Hodgkin Disease 39Recurrence 35Lymphoma, Large-Cell, Anaplastic 18Multiple Myeloma 16Neoplasms 13Myelodysplastic Syndromes 12Hematologic Neoplasms 12Leukemia, Myeloid, Acute 11Lymphoma, T-Cell 9Intraocular Lymphoma 9Dendritic Cell Sarcoma, Interdigitating 9Leukemia, Prolymphocytic 7Neoplasms, Plasma Cell 6Leukemia, Hairy Cell 6Leukemia, B-Cell 6Graft vs Host Disease 6Arthritis, Rheumatoid 6

Interventions

Etoposide 2Cyclophosphamide 2prednylidene 1fialuridine 1deltacortene 1Vorinostat 1Vincristine 1Salvia hispanica seed extract 1Rituximab 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Cytarabine 1Carmustine 1CT-P10 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, Primary Effusion × Rituximab × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡